is a biopharmaceutical organization dedicated
to "Cures for Mankind" that is strategically focused on diseases of aging and
development. The company expects to have two of
these programs in clinical trials in 2006. Baker, Ph.

rippey surnames

NVE Promotes Curt A. Reynders to Chief Financial Officer

Reynders earned a B.

batson spindel

Experts anticipate that AD
will affect millions more in the coming years if an effective treatment to
stop its progression is not made available. Richard L. Reynders has been promoted to the position of Chief
Financial Officer and Treasurer. Dick's skills will remain available to us, and we
are fortunate to have an accomplished, experienced individual in Curt to
assume the CFO role. NVE licenses its MRAM intellectual property and sells
spintronic sensors and couplers to revolutionize data sensing and
transmission.

vanderburgh counts

, Voyager Pharmaceutical Corp.M.

Past President of Siena College from 1989-1996, Father McConville
served as a Director for a wide range of organizations in the profit
and not-for-profit sectors.
Reynders , 43, has been NVE's controller since 2001. Before joining NVE he
served in various accounting, auditing and accounting management positions
with public accounting and industry firms.

reisinger spindel

This announcement coincides with the company's
current efforts to initiate pivotal trials later in the year for its AD
treatment.F., Chief
Scientific Officer.
Smith.
"We appreciate Dick's contributions to NVE over the past nearly 15 years,"
said NVE President and CEO Daniel A.

gedcom utt

Appointments Reflect Company's Continuing Momentum Toward a New Alzheimer's
Treatment

RALEIGH, N.D., and premature births.

utt counts

leatherman spindel

D.
Statements used in this press release that relate to future plans, events,
financial results or performance are forward-looking statements that are
subject to certain risks and uncertainties including the risk factors listed
from time to time in our filings with the SEC, including our Annual Report on
Form 10-KSB and other reports filed with the SEC.

horton sisk

, the
biopharmaceutical company with a primary focus on introducing a new treatment
for Alzheimer's disease (AD), today announced two prestigious new appointments
to its Board of Directors.5 million cases
in the United States alone.

robison gedcom

Smith, President and Chief Executive Officer; David J.

linn vanderburgh

He received an undergraduate degree (cum
laude) from Catholic University , a Master's Degree in Theology from
Washington Theological Union, and a Ph. Additional information is
available at Voyager's website, http://www.com.

George Retires as CFO

EDEN PRAIRIE, Minn. in
Accounting and Economics from Morningside College and is a Certified Public
Accountant .

Sites in which the primary focus is the etymology of the surname and its variants, a one-name study or organization, relevant genealogy, or an associated family history.

1800s connie

D.
"We are pleased to have such highly respected individuals with broad
experiences, join our knowledgeable and passionate team ," said Patrick S.

rippey sisk

Voyager's Invention Center, headed by Dr.

cahill pendleton

Voyager Pharmaceutical Corp. Selects New Members to Its Board of Directors

, Past President, Siena College
(Albany, New York )

Father Edward McConville brings 34 years of experience as an academic,
civic , and religious leader to the Voyager Board of Directors. In addition, approximately half of all nursing
home residents suffer from the disease or a related disorder.

utt esquivel

Corcoran, Executive
Vice President and Chief Financial Officer; and Richard Bowen, M.voyagerpharma.S.

connie sisk

Richard L.

swain pendleton

Artman served in a variety of technical and
professional roles at the global provider of audit, risk advisory, and
tax services, including being elected Partner in 1982. These monies will be used to support the launch of the ALADDIN
pivotal study later this year and further strengthen Voyager's balance sheet.L.

gedcom waitman

Patients
usually live from 8 to 10 years after diagnosis, and the average lifetime cost
per individual can be as high as $174,000 U. Voyager was incorporated in February 2001 to focus
on a treatment for AD., NVE Corporation
(Nasdaq: NVEC) announced today that Richard L.

reisinger jnr

Voyager Pharmaceutical Corp. "NVE has made tremendous
progress during his tenure.

reisinger dickerson

The company 's scientific platform is based on the peer-reviewed
published work of Dr. Bowen, Voyager's Chief Scientific Officer and
one of Voyager's founders.S.

sisk jnr

He has
unsurpassed experience in the oversight of financial and health care
organizations, as well as academic institutions, inter -collegiate
athletics, and the arts. "Professionals of this caliber will be a tremendous asset in helping
Voyager both set and meet its ambitious goals in the treatment of some of the
world 's most challenging afflictions.

About Alzheimer's Disease
An estimated 12 million people worldwide have AD, with 4.S. George retired as Chief
Financial Officer and Treasurer on January 16, 2006.

counts utt

The newest appointments to the Voyager Board of Directors include:

- Jim Artman, CPA, Retired Partner, KPMG LLP

Jim Artman is uniquely qualified to chair the Audit Committee for the
Voyager Board of Directors with more than 30 years of accounting and
auditing experience from KPMG LLP - based in the company's Raleigh,
North Carolina office. Christopher Gregory, is
conducting preclinical work in brain cancer, hormone refractory prostate
cancer, A."
NVE is a leader in the practical commercialization of spintronics, a
nanotechnology that many experts believe represents the next generation of
microelectronics.

robison shoaf

Artman worked in a number of critical capacities over his career:

* The Professional Practice Partner for the Carolinas Business Unit
* Securities and Exchange Commission (SEC) reviewing partner for the
firm
* Three-year assignment in the firm's national Department of
Professional Practice
* Engagement partner for numerous publicly-traded companies

In addition, he has established himself as a strong and active
contributor in North Carolina:

* College of Management Board of Advisors - North Carolina State
University
* Chair of Accreditation/Certification Committee - United Way of Wake
County
* Continuing Care Advisory Committee - North Carolina Department of
Insurance

- William Edward McConville, O.

These professionals will join existing Board of Directors' members Patrick
S. George will remain with
the company on a part -time basis concentrating on Government contract
administration. Curt A.

mccraw reisinger

C. in Systematic Theology from
Vanderbilt University.

mccraw horton

"
In related news, Voyager announced it has completed a $10+ million equity
placement, the majority of which was purchased by Voyager's existing
shareholders .

About Voyager Pharmaceutical Corp.